Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate ...

Eli Lilly and Company (NYSE: LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS (lebrikizumab-lbkz) in pediatric patients ...
pharmaphorum

Texas suit claims Lilly bribed providers to prescribe drugs

Eli Lilly has been accused of giving illegal inducements to encourage medical providers in Texas to prescribe its medicines in a new lawsuit backed by state Attorney General Ken Paxton. The scheme ...
University of Bristol

Postgraduate study

Bristol Dental School provides superb teaching and an excellent research environment for postgraduate studies. We have an active and integrated postgraduate community from a mixture of clinical, lab ...
Daily Record

Scottish Government

The Scottish Government, formerly the Scottish Executive, came into being in 1999 as a consequence of the Scotland Act of the previous year. It has powers devolved from Westminster to rule Scotland ...